Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
Open accessThe DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index; none of the 86 sources its claims cite is checked for support yet.
Abstract
At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence.
Overview
CoChat Summary
## TL;DR
This review argues that poor medication adherence in type 2 diabetes is common, often affecting at least half of patients, and is tied to worse glycemic control, higher costs, and higher mortality. It highlights two broad modifiable drivers: treatment burden and patients’ treatment-related beliefs.
## Key findings
- Reported poor medication adherence in T2D ranged from 38% to 93% across studies, largely because definitions and methods varied; using MPR ≥80%, adherence was 47.3% for dipeptidyl peptidase-4 inhibitors, 41.2% for sulfonylureas, and 36.7% for thiazolidinediones in a 238,000-patient MarketScan analysis.
- Poor adherence was associated with worse outcomes: among >11,000 veterans, MPR <80% was significantly associated with poor glycemic control (HbA1c >8%, P<0.001); in 1,198 survey respondents, each 1-point drop in self-reported adherence was linked to a 0.21% increase in HbA1c and increases of 4.6%, 20.4%, and 20.9% in physician, ER, and hospital visits.
- Mortality was higher with poor adherence: in 15,984 UK patients, poor adherence and missed visits were each associated with a 1.6-fold increase in all-cause mortality (P<0.001); another study reported an odds ratio of 1.8 (P<0.001).
- Economic impact was substantial: improved adherence was projected to reduce hospitalization/ER risk by 13%, worsening adherence to raise it by 15%, and one analysis estimated annual savings of $4.7 billion with improved adherence and $3.6 billion with reduced poor adherence.
## Methods
- Narrative review of the literature on medication adherence in T2D, focusing on the scope of the problem, consequences, key contributors, interventions, and future developments.
- The paper synthesizes findings from retrospective/observational claim-database studies, surveys, and meta-analyses; it cites examples including analyses of 238,000 MarketScan patients, >11,000 veterans, 1,198 survey respondents, and other large database studies.
- Main analysis is qualitative synthesis of reported adherence rates, outcomes, and modifiable contributors, with attention to common adherence metrics such as medication possession ratio (MPR) ≥80% and persistence definitions.
## Limitations
- The paper states that much of the evidence comes from retrospective or observational claim-database studies using widely varying definitions, making findings difficult to interpret.
- It states that intervention evidence is limited because adherence measures vary widely, hard outcomes are often lacking, interventions are not clearly explained, and follow-up is often inadequate.
- Evident from the text: this is a review, not a new primary study, so its conclusions depend on the quality and comparability of the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 1 Not valid · 57 Not checked · 17 Own results and interpretations
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In one study that tracked new prescriptions written electronically over a 12-month period for >75,000 patients, 31.4% of new prescriptions for diabetes drugs were never filled.25”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Scope of the problem
What the sources say
- Not matchedcites [25]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainn = 75,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia)”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
49 more claims
Create a free account to see all 75 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple factors contribute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication ef fi cacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2DM who discontinue or do not properly adhere to their therapy, there is an increased risk of microvascular and macrovascular complications [7], which can in turn increase healthcare costs further [5, 6].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from this survey highlight patient perspectives on reasons for treatment discontinuation among people with T2DM in the USA and UK and provide focal points for communication for these individuals when they are initiating new therapies [5].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the NICE guidance (NG28) and gastrointestinal tolerability are likely important drivers, early GLP‐1RA discontinuation is plausibly multifactorial and may also reflect perceived treatment effectiveness, complex dosing schedules, injection‐related barriers, limited access to diabetes education, economic constraints, and medication shortages. 19 , 32 , 33 , 34”
From Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Up to 50% of people with T2DM discontinue treatment by 1 year [5].”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945 · cited 2×
“65 A key element is the need for greater consistency when measuring medication adherence, which require better instruments and tools for assessment.”
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70021-0 · Cited by 1,195
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837 · cited 1×
“Even worse, it has been well documented that this cost burden has been inexorably growing worldwide.(10) A key contributor to the remarkably high rates of morbidity and mortality is chronic poor metabolic control, especially poor glycemic control.”
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726 · cited 1×
“41 In their comprehensive review of 76 studies, Claxton et al 42 found that the prescribed number of doses per day was inversely associated with medication adherence; indeed, the mean adherence across studies decreased progressively from 79% with a once-daily dose to 51% with a four times daily…”
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationPrimary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions
Fischer, M. A., Stedman, M. R., Lii, J., Vogeli, C., Shrank, W. H., Brookhart, M. A., & Weissman, J. S. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1253-9 · Cited by 572 · cited 1×
“25 This problem, often referred to as primary nonadherence, may be particularly relevant among patients who are refusing to initiate insulin or other injectable hypoglycemic therapy, typically due to injection phobia, inconvenience, poor patient–physician communication, and/or negative patient…”
Cited by
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
“Multiple factors contribute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication efficacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63).”
BackgroundDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Lifestyle factors, self-management and patient empowerment in diabetes care
Lambrinou, E., Hansen, T. B., & Beulens, J. W. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319885455 · Cited by 261
“5% of participants achieved good glycaemic control.(12) Access to resources and support systems, patients’ attitude and expected treatment efforts, comorbidities, disease duration and risk of hypoglycaemia are the main factors that are related to inadequate glucose control.”
BackgroundSubramanian, D. A., Langer, R., & Traverso, G. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01539-x · Cited by 242
“This is associated with increases in patient adherence, which translates into increases in the effectiveness of the treatment [1].”
BackgroundAddressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review
Okemah, J., Peng, J., & Quiñones, M. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0819-5 · Cited by 211
An Effective Model of Diabetes Care and Education: Revising the AADE7 Self-Care Behaviors ®
American Association of Diabetes Educators (2020) · The Diabetes Educator · doi:10.1177/0145721719894903 · Cited by 184
“The reasons for not taking medications as prescribed are multifactorial.(86,89) Given that”
BackgroundKhunti, S., Khunti, K., & Seidu, S. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819844694 · Cited by 182
Mountain, A., Patrice Lindsay, M., Teasell, R., Salbach, N. M., de Jong, A., Foley, N., Bhogal, S., Bains, N., Bowes, R., Cheung, D., et al. (2020) · International Journal of Stroke · doi:10.1177/1747493019897847 · Cited by 176
“This care gap has repercussions on patients, caregivers, and the health-care system as non-adherence to drug prescriptions is associated with significant increases in mortality, hospitalizations, and costs.(35,36) Roles such as stroke case managers and/or stroke system navigators are valuable additions to the stroke c…”
BackgroundCornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156
Andreozzi, F., Candido, R., Corrao, S., Fornengo, R., Giancaterini, A., Ponzani, P., Ponziani, M. C., Tuccinardi, F., & Mannino, D. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00559-7 · Cited by 128
Ionic liquid-mediated delivery of insulin to buccal mucosa
Vaidya, A., & Mitragotri, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.037 · Cited by 125
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 149
Personalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
“Patient factors may include lower educational attainment, lower income, perceptions around treatment efficacy and the actual impact of T2D on their health.(28) Clearly, these factors ought to be considered when approaching a holistic management strategy in T2D patients.”
BackgroundMirahmadizadeh, A., Khorshidsavar, H., Seif, M., & Sharifi, M. H. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00750-8 · Cited by 111
Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
Williams, D. M., Jones, H. F., & Stephens, J. W. (2022) · Dove Medical Press (Taylor and Francis Group) · Cited by 99
Real-world assessments of mySugr mobile health app
Debong, F., Mayer, H., & Kober, J. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0019 · Cited by 95
Horvath, A., Leber, B., Feldbacher, N., Tripolt, N. J., Rainer, F., Blesl, A., Trieb, M., Marsche, G., Sourij, H., & Stadlbauer, V. (2019) · European Journal of Nutrition · doi:10.1007/s00394-019-02135-w · Cited by 117
Lingvay, I., Buse, J. B., Franek, E., Hansen, M. V., Koefoed, M. M., Mathieu, C., Pettus, J., Stachlewska, K., & Rosenstock, J. (2021) · Diabetes Care · doi:10.2337/dc20-2878 · Cited by 110
Empowerment of patients with type 2 diabetes: current perspectives
Gómez‐Velasco, D., Almeda‐Valdés, P., Martagón, A. J., Galán-Ramírez, G. A., & Aguilar-Salinas, C. A. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s174910 · Cited by 122
Evans, M., Engberg, S., Faurby, M. D., Fernandes, J. D. D. R., Hudson, P., & Polonsky, W. H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14603 · Cited by 117
Self-citationIsmail, H., Marshall, V. D., Patel, M. R., Tariq, M., & Mohammad, R. A. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.11.013 · Cited by 93
Tamborlane, W. V., Laffel, L. M., Shehadeh, N., ISGANAITIS, E. M., Name, M. A. V., Ratnayake, J., Karlsson, C., & Norjavaara, E. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00052-3 · Cited by 90
Piragine, E., Petri, D., Martelli, A., Calderone, V., & Lucenteforte, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051981 · Cited by 147
Rinaldi, G., Hijazi, A., & Haghparast-Bidgoli, H. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108084 · Cited by 85
Polonsky, W. H., ARORA, R., Faurby, M. D., Fernandes, J. D. D. R., & Liebl, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01189-6 · Cited by 99
“outcomes such as mortality [25] and to reduce healthcare costs [28].”
BackgroundSelf-citationMedication Adherence and Diabetes Self-Care Activities Among Patients With Type 2 Diabetes Mellitus
Jannoo, Z., & Khan, N. M. (2018) · Value in Health Regional Issues · doi:10.1016/j.vhri.2018.06.003 · Cited by 98
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
Brunton, S., & Wysham, C. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798099 · Cited by 95
Willcox, M. L., Elugbaju, C., Al-Anbaki, M., Lown, M. T., & Graz, B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777561 · Cited by 87
“, 2013); poor adherence to medications is a major reason (Polonsky and Henry, 2016).”
BackgroundEfficacy of telemedicine on glycaemic control in patients with type 2 diabetes: A meta-analysis
De Groot, J., Wu, D., Flynn, D., Robertson, D., Grant, G., & Sun, J. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i2.170 · Cited by 77
Insulin Initiation and Titration in Patients With Type 2 Diabetes
Chun, J. H., Strong, J. L., & Urquhart, S. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0005 · Cited by 92
Nelson, L. A., Greevy, R. A., Spieker, A., Wallston, K. A., Elasy, T. A., Kripalani, S., Gentry, C., Bergner, E. M., LeStourgeon, L. M., Williamson, S. E., et al. (2021) · Diabetes Care · doi:10.2337/dc20-0961 · Cited by 74
Basiri, R., Seidu, B., & Rudich, M. (2023) · Nutrients · doi:10.3390/nu15194226 · Cited by 112
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70
“It is known that some patients prefer oral over injectable medications (44, 45), and lower treatment adherence has been reported with more frequent administration or when patients perceive the treatment as difficult or inconvenient (45, 46).”
BackgroundGupta, L., Khandelwal, D., Maharaj Agrasen Hopsital, P. B., Lal, P. R., Gupta, Y., Kalra, S., & Dutta, D. (2019) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2019.15.1.18 · Cited by 81
Böhm, A.-K., Schneider, U., Aberle, J., & Stargardt, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250993 · Cited by 73
Pettus, J., Roussel, R., Zhou, F. L., Bosnyák, Z., Westerbacka, J., Berria, R., Jiménez, J., Eliasson, B., HRAMIAK, I. M., Bailey, T. S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0568-8 · Cited by 67
“Experiencing hypoglycemia may contribute to reduced treatment adherence [3] as well as increased healthcare resource utilization and costs [4], and may also have clinical consequences such as increased risks of morbidity and mortality [5] and poorer health-related quality of life [5, 6].”
BackgroundKinnear, F. J., Wainwright, E. M., Perry, R. E., Lithander, F. E., Bayly, G. R., Huntley, A. L., Cox, J. S., Hamilton-Shield, J. P., & Searle, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030290 · Cited by 78
Sato, H., Yamada, K., Miyake, M., & Onoue, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122708 · Cited by 75
“Oral delivery is a desirable route of administration for various types of drugs since it is easy to use, noninvasive, painless, economical, and administered by patients [1].”
BackgroundFrías, J. P., Chien, J. Y., Zhang, Q., Chigutsa, E., Landschulz, W. H., Syring, K. E., Wullenweber, P. K., Haupt, A., & KAZDA, C. M. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00388-6 · Cited by 67
Diabetes duration and the risk of dementia: a cohort study based on German health claims data
Reinke, C., Buchmann, N., Fink, A., Tegeler, C., Demuth, I., & Doblhammer, G. (2021) · Age and Ageing · doi:10.1093/ageing/afab231 · Cited by 69
Bouldin, E. D., TRIVEDI, R. B., Reiber, G. E., Rosland, A.-M. M., Silverman, J. B., Krieger, J. W., & Nelson, K. M. (2017) · Chronic Illness · doi:10.1177/1742395317690032 · Cited by 64
Metabolic Disorders with Kidney Transplant
Cohen, E., Korah, M. M., Callender, G. G., Aguiar, R. B. D., & Haakinson, D. J. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09310819 · Cited by 65
Wahab, M., & Janaswamy, S. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.121967 · Cited by 56
Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment
Beran, D., Ewen, M. A., Lipska, K. J., Hirsch, I. B., & Yudkin, J. S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1019-z · Cited by 61
Sartori, A. C., Lucena, T. F. R., Lopes, C. T., Bernuci, M. P., & Yamaguchi, M. U. (2020) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2019.0305 · Cited by 71
“36 37–39 In addition, fast technological changes and the continuing need for learning about new technologies is a challenge for individuals older than 50 compared with younger subjects 40–42 and the continued development of new, smaller, and more complex smartphone models exacerbates the problem.”
Spooner, K., Guinan, G., Koller, S., Hong, T., & Chang, A. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s214098 · Cited by 52
Smoking increases the likelihood of Helicobacter pylori treatment failure
Itskoviz, D., Boltin, D., Leibovitzh, H., Perets, T. T., Comaneshter, D. S., Cohen, A. D., Niv, Y., & Levi, Z. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.03.010 · Cited by 55
Pantalone, K. M., Misra‐Hebert, A. D., Hobbs, T. M., Kong, S. X., Ji, X., Ganguly, R., Milinovich, A., Weng, W., Bauman, J. M., Petraro, P., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0968 · Cited by 60
“Poor treatment adherence is a well-known barrier to glycemicgoalattainment(45),andonethat we could not capture within the EHR data; future studies linking clinical EHR data and claims data (for adherence evaluation) would be valuable.”
BackgroundMody, R., Grabner, M., Yu, M. B., Turner, R., Kwan, A. Y. M., York, W., & Landó, L. F. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1421146 · Cited by 53
Sharma, D., & Singh, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.012 · Cited by 55
“Subsequently, 60% of people with type-1 DM and 45% of people with type-2 DM fail to achieve their target blood glucose levels [8,9].”
BackgroundZhang, C., Ye, F., Wang, J., He, P., Lei, M., Huang, L., Huang, A., Tang, P., Lin, H., Liao, Y., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00374 · Cited by 55
Application of Extrusion-Based 3D Printed Dosage Forms in the Treatment of Chronic Diseases
Annaji, M., Ramesh, S., Poudel, I., Govindarajulu, M., Arnold, R. D., Dhanasekaran, M., & Babu, R. J. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.09.042 · Cited by 54
Wilding, J. P. H., Godec, T. R., Khunti, K., Pocock, S., Fox, R. A., Smeeth, L. L., Clauson, P., Fenici, P., Hammar, N., & Medina, J. (2018) · BMC Medicine · doi:10.1186/s12916-018-1085-8 · Cited by 55
Jude, E. B., Malecki, M. T., Gomez Huelgas, R., Prazny, M., Snoek, F., Tankova, T., Giugliano, D., & Khunti, K. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01222-2 · Cited by 52
“Moreover, low adherence can be secondary to a fear of hypoglycaemia [20].”
BackgroundJanež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
“A proactive approach, including, in addition to the treating physician, the support of nurses, pharmacists, etc., in the management of the dis‑ ease has proved effective since patients respond better when they feel that somebody responds to their needs and problems [213, 214].”
BackgroundPalanca, A., Ampudia-Blasco, F. J., Calderón, J. M., Sauri, I., Martinez-Hervás, S., Trillo, J. L., Redón, J., & Real, J. T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01382-9 · Cited by 48
“Key barriers to optimal glycaemic control include nonadherence to diabetes therapy and lack of persistence with treatment over time, which represent an area of concern in the management of type 2 diabetes [4].”
BackgroundSeidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 63
Smith, F. N. C., Sabri, A. H. B., Heppel, M., Fonseca, I., Chowdhury, F., Cheung, K., Willmor, S., Rawson, F. J., & Marlow, M. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122234 · Cited by 51
“…to adhere to their therapeutic regimen and this has been attributed to lifestyle challenges, as shown by Peyrot et al , as well as medication side effects, demonstrated by García-P ´ erez et al (Cramer and Pugh, 2005; García-P ´ erez et al., 2013; Peyrot et al., 2010; Polonsky and Henry, 2016).”
Gow, K., Rashidi, A., & Whithead, L. (2023) · Current Diabetes Reports · doi:10.1007/s11892-023-01532-0 · Cited by 83
“This finding is echoed in previous studies indicating that people’s willingness to continue taking medication in the face of adverse effects decreased [29].”
ResultTibaldi, J. M., Hadley‐Brown, M., Liebl, A., Haldrup, S., Sandberg, V., Wolden, M. L., & Rodbard, H. W. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13616 · Cited by 50
“ing a barrier to treatment adherence and recovery of glycaemic control.(3) Received: 13 September 2018 Revised: 6 December 2018 Accepted: 13 December 2018”
BackgroundMannan, A., Hasan, M. M., Akter, F., Rana, M. M., Chowdhury, N. A., Rawal, L. B., & Biswas, T. (2021) · Global Health Action · doi:10.1080/16549716.2021.1872895 · Cited by 69
“According to many previous studies, poor patientprovider relationships, prolonged intervals while delivering diabetes education, side effects of medications, and pill burdens are common risk factors for nonadherence to diabetes treatments [17].”
BackgroundMethodSeidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 49
Papadogiannis, G., Bouloukaki, I., Mermigkis, C. M., Michelakis, S., Ermidou, C., Mauroudi, E., Moniaki, V., Tzanakis, Ν., Antoniou, K. M., & Schiza, S. E. (2020) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.8932 · Cited by 52
“37,38 In OSA treatment with PAP, despite the widespread adoption in clinical practice of a threshold approach of ≥ 4-hourPAPuseforor70%ofthenights, 39 itissuggestedthat the greater the number of hours of PAP use per night the greater the improvement in a range of outcomes, including sleepiness,…”
Dey, J. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1307081 · Cited by 44
“Poor medication adherence is fairly common in patients with T2DM and nearly half of patients with T2DM do not achieve adequate glycemic control (HbA1c <7%) [90].”
BackgroundGamede, M. W., Mabuza, L. P., Ngubane, P. S., & Khathi, A. (2019) · Molecules · doi:10.3390/molecules24020340 · Cited by 51
“The efficacy of these drugs is often impeded by low patient compliance resulting from neglecting dietary modification as well as the consumption of multiple medications at a single time [15].”
BackgroundCox, N., Gibas, S., Salisbury, M., Gomer, J., & Gibas, K. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2019.01.055 · Cited by 44
Del Prato, S., Kang, J., Trautmann, M. E., Stewart, J., Sorli, C. H., Derwahl, M., Soto, A., & Yoon, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14020 · Cited by 43
Krishnamoorthy, Y., Rajaa, S., Rehman, T., & Thulasingam, M. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055226 · Cited by 42
Smartphone Apps for Diabetes Medication Adherence: Systematic Review
Islam, S. M. S., Mishra, V., Siddiqui, M. U., Moses, J. C., Adibi, S., Nguyen, L., & Wickramasinghe, N. S. (2022) · JMIR Diabetes · doi:10.2196/33264 · Cited by 52
Balkhi, B. S., Alwhaibi, M., Alqahtani, N., Alhawassi, T. M., Alshammari, T. M., Mahmoud, M. A., AlMetwazi, M. S., Ata, S. I., & Kamal, K. M. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029280 · Cited by 55
Differential effects of vagus nerve stimulation strategies on glycemia and pancreatic secretions
Payne, S. C., Ward, G. M., MacIsaac, R. J., Hyakumura, T., Fallon, J. B., & Villalobos, J. (2020) · Physiological Reports · doi:10.14814/phy2.14479 · Cited by 45
“Medical adherence is worsened by the experience of unpleasant side effects, such as hypoglycemia (Polonsky & Henry, 2016; Walz et al., 2014), and with greater complexity of the medication administration regimen (Claxton, Cramer, & Pierce, 2001; Coleman et al., 2012; de Vries et al., 2014;…”
Backgroundd’Aquino, A. I., Maikawa, C. L., Nguyen, L. T., Lu, K., Hall, I. A., Jons, C. K., Kasse, C. M., Yan, J., Prossnitz, A. N., Chang, E., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101292 · Cited by 57
“7,8 The lack of adherence occurs primarily because of adverse effects, most commonly being hypoglycemia, weight gain, or gastrointestinal side effects, and complex treatment regimens.”
BackgroundInfluentialKrzemińska, S. A., Lomper, K., Chudiak, A., Ausili, D., & Uchmanowicz, I. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01628-z · Cited by 42
Pribish, A. M., Khalil, N., Mhaskar, R. S., Woodard, L. J., & Mirza, A. (2018) · Journal of Community Health · doi:10.1007/s10900-018-0580-3 · Cited by 42
Vinitha, R., Nanditha, A., Snehalatha, C., Satheesh, K., Susairaj, P., Raghavan, A., & Ramachandran, A. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107919 · Cited by 43
Roborel de Climens, A., Pain, E., Boss, A., & Shaunik, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00843-9 · Cited by 38
Lassen, M. C. H., Johansen, N. D., Modin, D., Catarig, A., Vistisen, B. K., Amadid, H., Zimmermann, E., Gislason, G., & Biering‐Sørensen, T. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15872 · Cited by 40
“17 Although the use of GLP-1RAs continues to increase, adherence to the medication remains suboptimal.”
Félix, I. B., Guerreiro, M. P., Cavaco, A. M. D. N., Cláudio, A. P., Mendes, A., Balsa, J., Carmo, M. B., Pimenta, N. M., & Henriques, M. A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00680 · Cited by 41
“…poor medication adherence should consider the reduction of the medication burden, not only from a drug perspective (e.g., using fixed combinations) but also tools for an easier therapy management, plus responding to negative medication beliefs (Polonsky and Henry, 2016; Capoccia et al., 2016).”
BackgroundIllness Perceptions, HbA1c, And Adherence In Type 2 Diabetes In Saudi Arabia
Alyami, M. M., Serlachius, A. S., Mokhtar, I., & Broadbent, E. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s228670 · Cited by 41
“Considerable evidence indicates that non-adherence to diabetes medication and other self-management behaviours among patients with T2D is common,(5) with less than 50% of patients achieving glycaemic control.(6) It is well recognized that non-adherence is a multifaceted problem, influenced by a wide range of factors i…”
BackgroundLeslie, W. S., Ali, E., Harris, L., Messow, C., Brosnahan, N., Thom, G., McCombie, L., Barnes, A. C., Sattar, N. A., Taylor, R., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05471-x · Cited by 43
“Although modern antihypertensive drugs are effective, it is well known that adherence to prescriptions for both diabetes and hypertension can be poor [30, 31] and the potential to be able to stop both antihypertensive and glucose-lowering medications legitimately was a major practical motivation for participants’ achi…”
BackgroundDapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes
Shehadeh, N., Barrett, T. G., Galassetti, P. R., Karlsson, C., Monyak, J. T., Iqbal, N., & Tamborlane, W. V. (2023) · NEJM Evidence · doi:10.1056/evidoa2300210 · Cited by 39
Pieber, T. R., Asong, M., Fluhr, G., Höller, V., Kristensen, N. R., LARSEN, J. H., Ribel‐Madsen, R., Švehlíková, E., VINTHER, S. M., Voortman, M. M., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15266 · Cited by 39
Tabong, P. T., Bawontuo, V., Dumah, D. N., Kyilleh, J. M., & Yempabe, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198915 · Cited by 40
Mody, R., Yu, M. B., Nepal, B., Кониг, М., & Grabner, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14195 · Cited by 40
“Despite the availability of multifaceted interventions, long-term, sustained improvements in medication adherence remain problematic for T2D treatment.(16) Long-term poor adherence and persistence can increase the financial burden of T2D,(8,9) thus it is essential to identify treatment options that offer sustained gly…”
BackgroundGomes, M. B., Tang, F., Chen, H., Cid‐Ruzafa, J., Fenici, P., Khunti, K. K., Rathmann, W., Shestakova, M. V., Surmont, F., Watada, H., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.831676 · Cited by 36
“Although thisfinding is concerning, studies in high-income countries have suggested that this association is due to a lackof engagementwith treatment reviews, rather than low socioeconomic status (33).”
BackgroundEspinoza, P., Varela, C. A., Vargas, I., Ortega, G., Silva, P. A., Boehmer, K. B., & Montori, V. M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241485 · Cited by 33
“The rigidity of the protocols fails to account for the importance of considering patient characteristics–such as patient’s perceptions and beliefs [17] when creating a health care plan [20] that makes practical sense in the Table 2.”
BackgroundTissue Engineering-Based Strategies for Diabetic Foot Ulcer Management
Chiu, A., Sharma, D., & Zhao, F. (2021) · Advances in Wound Care · doi:10.1089/wound.2021.0081 · Cited by 38
“96 Currently, no research has been published on the effect of DFU healing outcomes on diabetes medication adherence.”
Zairina, E., Nugraheni, G., Sulistyarini, A., et al. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00961-6 · Cited by 34
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 83
Exploring a New Theoretical Model to Explain the Behavior of Medication Adherence
Unni, E., & Bae, S. (2022) · Pharmacy · doi:10.3390/pharmacy10020043 · Cited by 49
Suprapti, B., Izzah, Z., Anjani, A. G., Andarsari, M. R., Nilamsari, W. P., & Nugroho, C. W. (2023) · Global Epidemiology · doi:10.1016/j.gloepi.2023.100113 · Cited by 42
Ray, A., Paik, J. M., Wexler, D. J., Sreedhara, S. K., Bykov, K., Feldman, W. B., & Patorno, E. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.7811 · Cited by 38
Huang, Y., Shiyanbola, O. O., Chan, H., & Smith, P. D. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1749499 · Cited by 46
“However, compared with patients’ demographic background, it may be more important to identify modifiable factors that are relevant to medication adherence and can be changed through intervention programs [18].”
BackgroundHazrati‐Meimaneh, Z., Amini‐Tehrani, M., Pourabbasi, A., Gharlipour, Z., Rahimi, F. C., Ranjbar-Shams, P., Nasli‐Esfahani, E., & Zamanian, H. (2020) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2020.110178 · Cited by 41
Factors Influencing Medication Non-Adherence among Chinese Older Adults with Diabetes Mellitus
Xu, N., Xie, S., Chen, Y., Li, J., & Sun, L. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17176012 · Cited by 47
“To relieve the heavy burden of disease directly and indirectly caused by DM, achieving the targets for glycemic control among patients with DM is crucial [7,8].”
BackgroundJiraporncharoen, W., Pinyopornpanish, K., Junjom, K., Dejkriengkraikul, N., Wisetborisut, A., Nadal, I. P., Hashmi, A., & Angkurawaranon, C. (2020) · BMC Family Practice · doi:10.1186/s12875-020-01233-7 · Cited by 35
“An important example of this is the fear of hypoglycemia, which has been attributed as a cause for patients to stop or self-adjust regimens [21], and adverse events associated with anti-diabetics have made patients in neighboring Malaysia [22] and further afield in Bangladesh [13] reluctant to adhere to therapeutic re…”
BackgroundPiragine, E., & Calderone, V. (2020) · Phytotherapy Research · doi:10.1002/ptr.6923 · Cited by 38
“In addition, at least 45% of T2DM patients fail to achieve adequate glycemic control, mainly due to poor medication adherence (Polonsky & Henry, 2016).”
Background
Metadata
- Authors
- Polonsky, W., & Henry, R.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Polonsky, William
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2016-07
- Volume
- Volume 10
- Pages
- 1299-1307
- ISSN
- 1177-889X (ISSN-L)
- PMC
- PMC4966497
- OpenAlex
- W2493860075
- Cited by
- 784
- References
- 77
- Citations by year
- 2026: 93 · 2025: 97 · 2024: 89 · 2023: 82 · 2022: 108 · 2021: 106 · 2020: 106 · 2019: 54 · 2018: 34 · 2017: 13 · 2016: 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Preference and Adherence (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- medication adherence, type 2 diabetes, glycemic control, barriers to adherence, medication beliefs, medication burden, out-of-pocket costs, hypoglycemia, treatment complexity, clinical inertia, socioeconomic factors, diabetes complications, drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.